Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WST11 Phototherapy for Upper Tract Urothelial Carcinoma
NCT03617003Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2018
- Primary completion
- Jul 2025
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of padeliporfin VTP in upper tract urothelial carcinoma (UTUC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum tolerated laser fluence rate at 2 years. Started Aug 2018; status: completed.
02
Drugs
padeliporfin VTP
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT03617003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617003.